Results 171 to 180 of about 602,267 (275)

Pediatric Clostridiodes difficile infection with toxic megacolon successfully treated with fecal microbiota transplantation

open access: yesJPGN Reports, Volume 7, Issue 4, Page 509-512, November 2026.
Abstract The rising incidence of pediatric Clostridioides difficile infection (CDI), particularly in medically complex patients, calls for novel, individualized treatments. While fecal microbiota transplantation (FMT) is well‐described for recurrent CDI, this report describes the first pediatric case of fulminant CDI with toxic megacolon successfully ...
Dana McCarney   +3 more
wiley   +1 more source

Efficacy and Safety of ramucirumab Combined With Nab‐paclitaxel, Lobaplatin, and S‐1 in Conversion Therapy for Unresectable Advanced Gastric Cancer: Preliminary Results of Conversion Therapy Cohort of RNPLS‐01 Trial

open access: yesMedComm, Volume 7, Issue 11, November 2026.
This study enrolled 70 HER2‐negative, unresectable stage III/IV gastric/gastroesophageal junction adenocarcinoma patients with over 6‐month survival, divided into RNPLS and NPLS groups (n = 35 each). Both groups received 21‐day‐cycle chemotherapy with lobaplatin, nab‐paclitaxel, and S‐1, while RNPLS additionally used ramucirumab.
Juan Wang   +12 more
wiley   +1 more source

Ovarian Carcinoma: Signal Pathways and Clinical Studies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
This review synthesizes current knowledge on the pathophysiological mechanisms driven by the Notch, HER2, DNA damage repair (DDR), PI3K/AKT/mTOR, and angiogenesis (VEGF) pathways in ovarian cancer. A key focus is placed on summarizing subsequent targeted therapeutic strategies, detailing the landscape of associated clinical trials and their ...
Yanru Long   +3 more
wiley   +1 more source

CRISPR Technology: From Bench to Bedside Applications

open access: yesMedComm, Volume 7, Issue 11, November 2026.
This review systematically dissects the molecular mechanisms, advantages, and limitations of core CRISPR editing platforms including base editors (Panel A) and prime editing (Panel B); summarizes pivotal clinical data across hemoglobinopathies, CAR‐T immunotherapy, muscular dystrophy, cystic fibrosis, cardiometabolic diseases, and rare monogenic ...
Xinzhi Ma, Lingyu Li, Yingli Sun
wiley   +1 more source

Evaluation of bone mineral density in patients with severe congenital neutropenia: experience of six centers in Turkey. [PDF]

open access: yesSci Rep
Karali Y   +12 more
europepmc   +1 more source

Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer

open access: yes
Clinical and Translational Medicine, Volume 16, Issue 11, November 2026.
Jesenia M. Perez   +3 more
wiley   +1 more source

Liquid Biopsy: Past, Present, and Future

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Liquid biopsy has expanded from cancer genotyping to a broader strategy for probing both oncologic and nononcologic conditions through circulating analytes and multilayer molecular readouts. This review traces the field's past, present, and future—summarizing where liquid biopsy is most actionable today, why performance varies across contexts, and ...
Jiachen Liu   +8 more
wiley   +1 more source

Alzheimer's Disease: Mechanisms and Therapeutic Advances

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Alzheimer's disease involves Aβ/tau aggregation, neuroinflammation, BBB leakage, gut–brain dysfunction, and mitochondrial damage, causing neuronal loss. Nanodelivery enables combined small‐molecule and targeted therapies. Disease‐modifying biologics/chemicals, including anti‐Aβ antibodies, raise safety and access concerns. Exercise, cognitive training,
Gaoshuang Fu   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy